Latest: Watch here for details of new products and services.
- About Us
- Pharmalicensing - Open Innovation for the life sciences
- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Due Diligence
- Comparison
- Due Diligence
- Overview
- Top Applications
- Online Panel Discussions
- Request Consultation
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire
- Jobs
- Forums
- Contact Pharmalicensing
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
Pharmalicensing Ltd
is a division of
is a division of
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
The First Line of Therapy in Severe Migraine Attacks More
4 and 8 mg Ondansetron ready for submission in EU (exp. Q4/08) using the proprietary RapidFilm drug delivery Technology securing fast dissolution in the oral cavity without the need of water More
Two new compounds having HDAC (histone deacetylase) inhibition capability have shown the effect of inducing re-differentiation of human brain and breast cancer cells both in vitro and in vivo. More
The first pure, immediate release (Tmax in 13,68 min), completely palatable and free from aftertaste diclofenac potassium formulation in drops at 5% available on the market More
A novel mixture of traditional Chinese medicines with anti-platelet aggregation and anti-thrombotic activity for both prevention and treatment of cerebral stroke. More
A new veterinary medicinal composition designed to maintain the oxygenic consumption, to restore hydric, electrolytic and energetic status, as well as the blood pH in affected mammals. More
A number of specific PPLs, a group of prenylflavanone compounds, some novel, were isolated, identified and tested at as low as 0.04 μg/mL to be able to increase survival of neural stem cells, to promote neuronal growth with lengthening of neurite More
Western researchers have developed a novel technique, Swallowing Air-Pulse Therapy (SWAPT) and an associated device Swallowing Air-Pulse Therapy System (SWAPTS). More
Posidorm is an unique surge sustained formulation of melatonin that provides 0.5mg of melatonin as an immediate release to promote sleep and 1.0mg as sustained release over several hours to maintain sleep More
Advatab™ Paracetamol combines 2 of Eurand's proprietary technologies AdvaTab™ and Microcaps® for highly effective taste-masking More
Your selection
Browse By
- Industry sector
- Generics
- Nutrition
- OTC/Non-Prescription
- Pediatric
- Personal Care
- Prescription
- Therapeutic target
- Attention-deficit/hyperactivity disorder
- Autism
- Brain injury
- Cerebral palsy
- Cerebrovascular disorders
- Dyslexia
- Emesis
- Encephalitis
- Epilepsy
- Huntington's disease
- Hypersomnia
- Insomnia
- Meningitis, aseptic
- Meningitis, bacterial
- Meningitis, viral
- Migraine
- Myalgic encephalomyelitis
- Narcolepsy
- Neoplastic meningitis
- Nerve regeneration
- Neuropathy, AIDS-related
- Neuropathy, diabetic
- Neuropathy, peripheral
- Neuroprotection
- Premenstrual dysphoric disorder
- Sleep apnea
- Sleep disorders
- Spasticity
- Spinal cord injury
- Stroke
- Tourette's syndrome
- Vertigo
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us